Biohaven Ltd. (NYSE:BHVN - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Biohaven in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($6.65) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Biohaven's current full-year earnings is ($8.90) per share.
Other analysts also recently issued reports about the company. Robert W. Baird decreased their price objective on Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a report on Monday, April 28th. Royal Bank of Canada downgraded shares of Biohaven from an "outperform" rating to a "sector perform" rating and cut their target price for the company from $54.00 to $21.00 in a research report on Monday, May 19th. JPMorgan Chase & Co. lowered their price target on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. William Blair raised shares of Biohaven to a "strong-buy" rating in a report on Thursday, April 24th. Finally, Morgan Stanley reduced their price objective on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $59.46.
View Our Latest Stock Report on Biohaven
Biohaven Price Performance
Shares of BHVN stock traded down $0.16 during mid-day trading on Tuesday, hitting $15.43. The stock had a trading volume of 1,362,300 shares, compared to its average volume of 1,265,266. Biohaven has a 12-month low of $14.33 and a 12-month high of $55.70. The firm's 50-day moving average is $18.21 and its two-hundred day moving average is $29.74. The firm has a market capitalization of $1.58 billion, a P/E ratio of -1.65 and a beta of 0.95.
Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($2.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.50).
Hedge Funds Weigh In On Biohaven
Several institutional investors and hedge funds have recently bought and sold shares of BHVN. Spire Wealth Management purchased a new stake in Biohaven in the fourth quarter valued at about $56,000. WCM Investment Management LLC purchased a new stake in Biohaven in the fourth quarter valued at approximately $3,816,000. Rhumbline Advisers increased its holdings in Biohaven by 14.0% in the 4th quarter. Rhumbline Advisers now owns 117,595 shares of the company's stock worth $4,392,000 after buying an additional 14,407 shares during the period. Principal Financial Group Inc. raised its position in Biohaven by 4.4% during the 4th quarter. Principal Financial Group Inc. now owns 77,387 shares of the company's stock worth $2,890,000 after buying an additional 3,281 shares during the last quarter. Finally, Peregrine Capital Management LLC acquired a new stake in Biohaven during the 4th quarter valued at approximately $5,561,000. 88.78% of the stock is owned by hedge funds and other institutional investors.
About Biohaven
(
Get Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Read More
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
